Singleminded-2s (SIM2s) is a member of the bHLH/PAS family of transcription factors and a key regulator of mammary epithelial cell differentiation. SIM2s is highly expressed in mammary epithelial cells and downregulated in human breast cancer. Loss of Sim2s causes aberrant mouse mammary ductal development, with features suggestive of malignant transformation, whereas overexpression of SIM2s promotes precocious alveolar differentiation in nulliparous mouse mammary glands, suggesting that SIM2s is required for establishing and enhancing mammary gland differentiation. To test the hypothesis that SIM2s regulates tumor cell differentiation, we analyzed SIM2s expression in human primary breast ductal carcinoma in situ (DCIS) samples and found that SIM2s is lost with progression from DCIS to invasive ductal cancer (IDC). Using a MCF10DCIS.COM progression model, we have shown that SIM2s expression is decreased in MCF10DCIS.COM cells compared with MCF10A cells, and reestablishment of SIM2s in MCF10DCIS.COM cells significantly inhibits growth and invasion both in vitro and in vivo. Analysis of SIM2s-MCF10DCIS.com tumors showed that SIM2s promoted a more differentiated tumor phenotype including the expression of a broad range of luminal markers (CSN2 (b-casein), CDH1 (E-cadherin), and KER18 (keratin-18)) and suppressed genes associated with stem cell maintenance and a basal phenotype (SMO (smoothened), p63, SLUG (snail-2), KER14 (keratin-14) and VIM (vimentin)). Furthermore, loss of SIM2s expression in MCF10DCIS.COM xenografts resulted in a more invasive phenotype and increased lung metastasis likely due to an increase in Hedgehog signaling and matrix metalloproteinase expression. Together, these exciting new data support a role for SIM2s in promoting human breast tumor differentiation and maintaining epithelial integrity.
INTRODUCTION
Ductal Carcinoma In Situ (DCIS) has been shown to be a precursor to invasive ductal cancer (IDC), 1 with 20-30% of DCIS showing evidence of invasion upon diagnosis. 2, 3 Although the progression of DCIS to IDC is believed to be an important aspect of tumor aggressiveness, prognosis and molecular markers that can predict progression are poorly understood. Analysis of biomarkers and molecular profiles of IDC and DCIS have failed to identify progression-specific pathways. [4] [5] [6] [7] [8] Therefore, determining the mechanisms by which some DCIS progress is critical for future breast cancer diagnostics and treatment.
There is increasing evidence that DCIS are heterogeneous tumors, which enhances complexity when attempting to define the mechanisms that promote progression to IDC in in vivo models. Recent studies utilizing the MCF10DCIS.COM cell line, which was derived from the noncancerous MCF10A cell line, have shown that these cells contain a unique bipotent progenitor ability to form a myoepithelial cell layer in addition to luminal-type cells in vivo, which results in basal-like DCIS with high similarities to human DCIS samples. [9] [10] [11] [12] [13] Intraductal and flank injections have shown that MCF10DCIS.COM cells not only form DCIS-like structures but also spontaneously progress to invasive breast cancer. 9, 11 These observations suggest that MCF10DCIS.COM cells are a unique model to study DCIS, as well as the role of different factors in regulating the progression to IDC.
We have previously shown that the basic helix-loop-helix/PER-ARNT-SIM (bHLH/PAS) transcription factor Singleminded-2s (SIM2s) has a role in normal mammary gland development, as well as in promoting tumor cell differentiation. [14] [15] [16] [17] [18] Loss of Sim2s expression in the mouse mammary gland and in normal breast and breast cancer cell lines is associated with an epithelial mesenchymal transition (EMT), whereas overexpression of Sim2s under the mouse mammary tumor virus promoter induces precocious alveolar differentiation in nulliparous mice and delayed forced involution. [14] [15] [16] [17] [18] SIM2s is downregulated in primary human breast cancer samples, and reestablishment of SIM2s in human breast cancer cell lines inhibits cell proliferation and invasion. 15, 17 Moreover, we have found that SIM2s mRNA gene expression is inhibited by activation of C/EBPb and NOTCH signaling, two known EMT promoters, in RAS-transformed MCF10A cells. 15 Both C/EBPb and NOTCH expression have been shown to have a role in breast cancer progression through mediation of breast cancer stem cells' cellular proliferation and oncogenesis. [19] [20] [21] [22] [23] Together, these observations suggest that SIM2s is a tumor-suppressor gene that is required to maintain epithelial integrity by inhibiting EMT-like pathways and promoting differentiation.
In the studies here, we examined the role of SIM2s in regulating the progression of DCIS to IDC and metastasis while promoting the less-aggressive, luminal-like breast cancer subtype. On the basis of our studies of SIM2s as a breast cancer tumor suppressor, we hypothesize that SIM2s expression will decrease spontaneous metastasis seen in the MCF10DCIS.COM model, and have a role in the inhibition of DCIS progression.
RESULTS

SIM2s is lost during DCIS progression
To determine the role of SIM2s in progression from DCIS to IDC, 14 human primary DCIS and IDC samples were analyzed for SIM2s expression by immunohistochemistry. We have previously shown that SIM2s is localized in the nuclei of human breast and mouse mammary ductal epithelial cells, 16, 17 and similar punctate staining was observed in normal ductal structures surrounding the tumors analyzed ( Figure 1a ). In these studies, we found that SIM2s expression is prominent in both the nucleus and cytoplasm in over 75% of DCIS samples (Figure 1b ), suggesting a loss in localization at the onset of progression. In contrast, as DCIS progresses to IDC, SIM2s staining is markedly downregulated, with no evidence of nuclear expression in over 80% of IDC samples (Figure 1c ), supporting a role for loss of SIM2s in breast cancer progression.
Reestablishment of SIM2s in the MCF10.DCIS.COM cell line induces genetic and morphologic changes in vitro MCF10DCIS.COM cells are a unique human breast cancer cell line that form DCIS-like lesions in in vivo mouse models, similar to primary human DCIS lesions, and spontaneously progress to invasive cancer. 13 In addition, MCF10DCIS.COM cells are thought to contain a bipotent progenitor population that generates both myoepithelial and luminal cells, mimicking the heterogeneity observed in human DCIS tumors. 9, 11 Quantitative real-time PCR (Q-PCR) analysis of SIM2s levels showed that SIM2s is significantly downregulated in MCF10DCIS.COM cells compared with parent MCF10A cells; however, SIM2s levels are still higher in MCF10DCIS.COM cells than levels found in luminal MCF7 and basal MDA.MB.231 cell lines, suggesting that SIM2s expression is lost with progression ( Figure 2a ). To determine the effect of SIM2s loss and gain of function, we stably transduced MCF10DCIS.COM cells with SIM2s and previously validated SIM2s-shRNA (SIM2si) lentiviruses. 15, 16 SIM2s levels and localization were confirmed using Q-PCR and immunofluorescence (Figures 2b-d) (Supplemental Figure 1 ). Q-PCR analysis of SIM2s mRNA levels shows an approximate 80% loss of expression in SIM2si cells compared with scrambled controls (Figure 2d ). In growth assays, SIM2s inhibited cell proliferation, whereas loss of SIM2s led to a significant increase in proliferation as compared with scrambled controls (Figure 2e ). We observed no change in invasive potential with SIM2s overexpression in Boyden chamber assays; however, there was a significant increase in invasion in the SIM2si cells ( Figure 2f ). Q-PCR analysis also showed a significant increase in E-Cadherin (CDH1) expression with SIM2s expression, as well as a decrease with SIM2si ( Figure 2g ). Similarly, p21, an important senescence and cell cycle regulator, was also significantly altered in response to SIM2s (Figure 2h ).
In vivo analysis of transduced MCF10DCIS.com cell xenografts show changes in growth and morphology Similar to the in vitro results, we found that SIM2s xenograft tumors grew significantly slower than controls (Figures 3a and b) . In contrast to our in vitro observations, we were surprised to find that downregulation of SIM2s led to a decreased trend in tumor size and weight as compared with scrambled controls; however, statistical significance was not obtained (Figures 3a and b ). To determine whether SIM2s expression affected changes in tumor morphology, we analyzed hematoxylin-and eosin-stained sections from SIM2s and SIM2si tumors. Histological analysis confirmed distinct phenotypic differences with SIM2s expression ( Figure 3d ): SIM2s tumors had a more differentiated phenotype including lobular-like structures with intact myoepithelial layers, whereas SIM2si tumors, despite growing at a slower rate, were more invasive and had large necrotic areas as compared with scrambled controls (Figure 3d , invasion shown by arrows). These observations are similar to previous studies that found no correlation between MCF10DCIS.COM growth in vivo and invasive potential, and support the hypothesis that SIM2s inhibits DCIS progression by promoting and maintaining a luminal phenotype. 9, 11, 12 Immunohistological analysis of tumors confirmed that SIM2s and SIM2si tumors continued to overexpress or knock down SIM2s protein levels in vivo (Figure 3e ). Q-PCR analysis of SIM2s levels confirmed an approximate 50% knockdown of SIM2s expression in SIM2si xenografts ( Figure 3c ).
SIM2s inhibits the expression of basal breast cancer markers
We have previously established that SIM2s is a negative regulator of EMT and promotes mammary gland differentiation in vitro and in vivo. 14, 17, 18 To determine whether the morphological changes associated with SIM2s expression in MCF10DCIS.COM xenografts are similar to our previous gain-and loss-of-function studies in the mouse mammary gland, we examined basal markers involved in breast cancer progression and EMT via Q-PCR and immunohistochemical analysis. Immunostaining for basal markers including keratin 14 (KER14), alpha-smooth muscle actin (aSMA), vimentin (VIM) and p63 shows a decrease in staining in SIM2s-overexpressing MCF10DCIS.COM tumors, and upregulation with loss of SIM2s (Figures 4a-d) . Moreover, indicative of enhanced tumor aggressiveness and progression, we observed an increase in colocalization of KER5 and VIM in SIM2si tumors ( Figure 4e and Supplemental Figure 2 ). Further analysis of EMT and basal markers, including the EMT transcription factor, SLUG, which we have previously shown as directly regulated and suppressed by SIM2s, was significantly decreased in SIM2s tumors along with SMA and p63 (Figures 4f,g and i). These results are consistent with SIM2s's role in mammary gland differentiation as p63, smoothened (SMO) and SLUG regulate cell differentiation and stem cell maintenance, which suggests that reestablishment of SIM2s is sufficient to promote a decrease in basal breast cancer markers. [24] [25] [26] [27] [28] [29] [30] Analysis of p21 mRNA levels also showed a decrease in SIM2si xenografts, similar to what was seen in vitro ( Figure 4h ). p21 is an important cell cycle regulator and is involved in the p53 stress-response pathway, as well as in senescence. [31] [32] [33] SIM2s promotes the expression of luminal markers To determine whether differential expression of SIM2s regulates prominent luminal markers in DCIS xenografts, we evaluated the expression of CDH1, keratin-18 (KER18) and Mucin-1 (MUC1). Immunostaining results for CDH1 showed increased trends and localization to the cellular membrane in the SIM2s-overexpressing tumors, and a decrease in localized staining with SIM2si tumors (Figure 5a ). Interestingly, Q-PCR analysis of CDH1 showed no significant changes with SIM2s overexpression; however, SIM2si tumors had significantly lower levels of CDH1 mRNA compared with controls ( Figure 5d ). Analysis of KER18 showed a significant positive relationship with SIM2s expression; KER18 protein and mRNA levels were elevated in SIM2s tumors, and protein appeared to be decreased with loss of SIM2s (Figures 5b and e ). MUC1, an apical luminal marker that is often mislocalized in cancer, showed an increase in apical staining in SIM2s xenografts, whereas a loss of localization is seen in SIM2si tumors (Figures 5c). In addition, we also examined changes in the transcription factor GATA3, a prognostic factor associated with positive breast cancer outcome and regulator of breast tumor cell differentiation. 34, 35 Analysis of GATA3 mRNA expression showed no differences in SIM2s expression, indicating that the differentiation phenotype associated with SIM2s expression appears to be GATA3 independent in this model (Figure 5g ). To determine whether SIM2s tumors undergo partial lactogenic differentiation, we also examined the expression of the milk protein b-casein (CSN2). Immunostaining for b-casein in SIM2s tumors not only showed increased protein expression over controls but also secretory globule formation indicative of milk protein expression as seen in the lactating mammary gland (Figure 5h, arrows) , and a distinct trend in CSN2 mRNA gene expression in SIM2s tumors (Figures 5f  and h) . Overall, these data support the hypothesis that the expression of SIM2s induces a luminal phenotype, including expression of milk proteins, whereas loss of SIM2s significantly decreases the expression of luminal markers.
Angiogenesis and metastasis are inhibited by SIM2s
We have shown that gain and loss of SIM2s expression in MCF10DCIS.COM correlates with phenotypic changes in invasive behavior and expression of luminal and basal differentiation markers. To investigate whether these phenotypic differences affect cancer progression and metastasis, we analyzed lungs from tumor-bearing mice for VIM, which is expressed in MCF10DCIS.-COM cells, but not in normal lung tissue. 36 The results showed positive VIM staining in lungs from control and scrambled tumors; however, we did not detect VIM expression in lungs from mice with SIM2s-expressing tumors (Figures 6a and c) . To confirm SIM2sdependent changes in progression, we performed Q-PCR analysis for human-specific b-2-globulin (b2M) gene expression in mouse lungs, which has been previously shown as an indicator of human cells in mouse lung tissues either because of metastasis or circulating tumor cells. 36 Although moderate levels of b2M expression were observed in control tissues, we did not detect b2M expression in lung tissue from mice with SIM2s-overexpressing tumors (Figure 6b ). In contrast, the majority of the lungs from mice with SIM2si tumors had high levels of b2M expression ( Figure 6b ). Consistent with differences in metastatic potential and SIM2s expression, we observed a decrease in angiogenesis in SIM2s tumors compared with controls (Figures 6d and e ) Interestingly, this difference is seen without taking into account the drastic change in tumor size ( Figure 6e ). In contrast, no significant change in angiogenesis was seen with loss of SIM2s, indicating that the increase in metastasis is due to other metastatic processes.
SIM2s-dependent regulation of matrix metalloproteinase and Hedgehog signaling
We have previously shown cell-type-specific SIM2s-dependent regulation of matrix metalloproteinase (MMP). These studies found that SIM2s binds to the MMP3 promoter and inhibits MMP3 expression in MDA.MB.435 cells, 17 whereas MMP2 expression is increased in MCF7-SIM2si cells and mouse Sim2s knockout mammary glands. 16 Using Q-PCR, we examined MMP gene expression in SIM2s-overexpressing and -underexpressing tumors (Figure 7) . The results show that SIM2s xenografts have decreased MMP expression, whereas SIM2si tumors have increased MMP levels (Figures 7a-d ). In addition, the Hedgehog signaling pathway has been shown to be overexpressed in breast cancer and play a role in proliferation and differentiation. 27, 28 Analysis of Indian Hedgehog and SMO by Q-PCR showed a drastic increase in Indian Hedgehog and SMO mRNA levels with loss of SIM2s (Figures 7e and f) .
DISCUSSION
There is significant evidence that relates the differentiation status of a tumor with its metastatic potential. [37] [38] [39] Analysis of luminal markers by microarray analysis and immunohistochemistry has confirmed that loss of epithelial characteristics correlates with an increase in cancer progression. [40] [41] [42] [43] Although pathways have been identified that promote differentiation, few molecules have been identified that maintain and enhance the differentiation potential. We have previously shown that SIM2s is a negative regulator of EMT in normal breast, breast cancer cell lines and the mouse mammary gland by suppressing SLUG and MMP2 gene transcription. 16, 17 In contrast, overexpression of Sim2s in the mouse mammary gland under the mouse mammary tumor virus promoter induces precocious lactogenic differentiation in virgin mice and delayed involution following forced weaning. 14, 18 Together, these observations led us to hypothesize that the expression of SIM2s in breast cancer would inhibit tumor growth by regulating differentiation potential. We report here that SIM2s expression is lost in human DCIS progression to invasive breast cancer, and by using the MCF10DCIS.com progression model we demonstrate that reestablishment of SIM2s promotes a more luminal-like phenotype, whereas downregulation of SIM2s leads to an increase in invasive potential. These new data support a role for SIM2s in regulating epithelial identity and a potential novel molecular target for differentiation therapy.
At the onset of xenograft studies, as expected, we observed that tumors overexpressing SIM2s grew at a slower rate, as compared with controls, with lower amounts of necrosis. Surprisingly, we found that SIM2si tumors exhibited a decreased trend in growth compared with scrambled controls. However, upon histological analysis, we observed a more invasive phenotype and large necrotic areas in the SIM2si tumors. In comedo DCIS, necrotic centers have been implicated as a more rapidly progressing DCIS with a worse prognosis compared with DCIS lacking necrosis. 12 Further analysis of luminal and basal-like breast cancer markers showed distinct trends regarding SIM2s gain and loss of function. We observed that basal markers were inhibited in SIM2s tumors, with upward trends occurring in SIM2si tumors. Conversely, when examining luminal markers, we found an increase either in the appropriate localization (CDH1 and MUC1) or in the increased expression with SIM2s tumors and a loss of localization and expression with SIM2si. Another unique expression pattern was the presence of aSMA in the SIM2s-overexpressing tumors. We anticipated that reestablishment of SIM2s in MCF10DCIS.COM cells would inhibit the bipotent progenitor capabilities of the cell line, and thus prevent the development of a myoepithelial layer in vivo. Surprisingly, however, SIM2s did not affect the bipotent progenitor ability. The significant decrease in SMA mRNA expression seen in SIM2s tumors could possibly be due to the smaller size of the tumors and lobular units rather than a biologically significant change in SMA expression. Finally, the expression of CSN2 in SIM2s tumors further indicates that not only does reestablishment of SIM2s maintain epithelial integrity but also promotes functional differentiation.
Recent studies have identified a number of transcription factor cascades that control key events in regulating mammary epithelial differentiation including GATA3, ELF5, NOTCH and C/EBPb. 21, 22, 35, 44 For instance, analysis of Gata3 conditional knockout mammary glands found an increase in luminal progenitor cells during alveolar differentiation and a defect in virgin ductal morphogenesis as a result of compromised estrogen responsiveness, 34 whereas loss of Elf5 has no effect on virgin development and exclusively regulates alveolar cell fate. 45 Although these factors have key roles in promoting differentiation along the luminal lineage, it begs the question: what maintains mammary ductal epithelial cells in a differentiated state and keeps them from de-differentiating and acquiring stem cell characteristics? It can be hypothesized that this/these factor(s) may target pathways regulating tumor-initiating cell self-renewal by blocking induction of EMT and maintaining epithelial integrity. Interestingly, studies with GATA3 have shown that while overexpression is sufficient to promote epithelial differentiation forced loss of GATA3 is not tolerated. 35 With SIM2s we observed that while overexpression is sufficient to induce differentiation, loss of expression promotes malignant transformation. Moreover, the lack of change in GATA3 in the SIM2s tumors, which has been shown to promote differentiation and inhibit breast cancer growth and metastasis, indicates that SIM2s is operating independently of GATA3. This has significant implications for our understanding of normal mammary development and breast cancer progression by introducing a novel pathway that may have a role in maintaining tumor-initiating cells or in promoting functional differentiation.
One of the most interesting phenotypes of this study was the marked increase in lung metastasis with loss of SIM2s. MMPs have long been attributed as having a key role in breast cancer invasion and [46] [47] [48] [49] [50] are integral to the degradation of the basement membrane during normal biology functions including mammary gland involution and lobular development. 14, [50] [51] [52] [53] [54] [55] [56] Previous work in our laboratory has shown that SIM2s differentially regulates MMP2 and MMP3 gene expression. 16, 17 In the study here, we observed a SIM2s-dependent regulation of MMP gene expression in SIM2s-overexpressing and -underexpressing DCIS xenografts. We showed that MMP1 and MMP10 were significantly decreased by SIM2s expression, whereas MMP3 was significantly increased by loss of SIM2s, accompanied by increased trends in other MMPs analyzed. These data indicate that a likely mechanism for SIM2s' effect on metastasis may be through a global regulation of MMPs in a complex and varied manner. Hedgehog signaling has also been implicated in breast cancer progression and invasion, as well as in the maintenance of cancer stem cells. 27, 28, 57, 58 In our study, the increase in SMO expression in SIM2si tumors is unique, as SMO upregulation in tumors causes a phenotype similar to that seen in SIM2si tumors and Sim2s knockout mammary glands, including increased proliferation and altered differentiation, possibly indicating interaction between these genes. 28 Studies in gastric and ovarian cancer have also connected Hedgehog signaling with invasion and MMP expression, 59,60 suggesting a potential mechanism of action by which SIM2s inhibits invasion and metastasis in vivo.
These observations provide a possible mechanism for the promotion of tumor differentiation through reestablishment of SIM2s, as well as possible roles for SIM2s in breast cancer progression. Determining at what point of the metastatic cascade SIM2s functions will be key in understanding SIM2s' role in breast cancer progression. Moreover, the use of established metastatic models and the impact of SIM2s on breast cancer subtypes will help elucidate the mechanism by which SIM2s affects tumor progression, as well as its possible effect on tumor-initiating cells. Together, these results suggest that SIM2s has the potential to be a novel target for differentiation therapy by inhibiting or reversing breast cancer progression.
MATERIALS AND METHODS
Cell Culture MCF10DCIS cells were generously provided by Dr Dan Medina (Baylor College of Medicine, Houston, TX, USA) and maintained in DMEM-F12 (Invitrogen, Carlsbad, CA, USA) with 10% horse serum (Atlanta Biologicals, Lawrenceville, GA, USA). HEK-293T Ampho-Phoenix packaging cells were obtained with permission from Gary Nolan at Stanford University and maintained as recommended.
Plasmids and Lentiviral Transductions
Lentiviral transduction of MCF10DCIS.com cells was performed as previously described. 17 Lentiviral transduction, SIM2s shRNA and SIM2s overexpression plasmids have been previously described. [15] [16] [17] 
Invasion assays
Invasion was measured using control and Matrigel-coated invasion chambers (Falcon BD, Franklin Lakes, NJ, USA). A total of 12 500 cells were seeded in serum-free Dulbecco's modified Eagle's medium (DMEM-F12, Invitrogen) in the upper chamber, with serum-containing medium in the lower chamber as a chemo attractant. After 18 h at 37 1C, cells were scraped from the upper chamber with a cotton swab, and the undersides of the membranes were fixed in 3.8% paraformaldehyde (Sigma, St Louis, MO, USA), stained with DAPI (4 0 ,6 0 -diamidino-2-phenylindole) (Invitrogen) and counted. The percent invasion was calculated according to the manufacturer's instructions.
Proliferation assays
Proliferation was measured using a Coulter particle counter. A total of 15 000 cells of each transduction were plated in triplicates on six-well plates, and then every 24 h the cells were trypsinized and counted in triplicate. The procedure continued for 6 days, or until the cells reached 100% confluency.
Xenograft studies
For xenograft studies, MCFDCIS.com cells (50 000) were injected subcutaneously into 8-to 14-week-old female nude mice in 50% Matrigel (BD Biosciences, Bedford, MA, USA). Tumors were allowed to grow for 18 days, and were measured using calipers starting on day 13. Xenografts were weighed at harvest and either snap-frozen in liquid nitrogen and stored at À 80 1C for DNA/RNA purification or formalin-fixed and paraffinembedded. Animal experiments were conducted following protocols approved by the Texas A&M Animal Care and Use Committee.
Immunostaining
Immunostaining was carried out as previously described. 17 Samples were incubated in blocking solution for 1 h, followed by incubation in primary antibody overnight at 4 1C. Antibodies used were SIM2s (Santa Cruz, Santa Cruz, CA, USA), SMA (Sigma), Keratin 14 (Covance, Princeton, NJ, USA), Vimentin (Sigma), p63 (NeoMarkers, Freemont, CA, USA), Keratin 5 (Covance), E-Cadherin (Cell Signaling, Beverly, MA, USA), Keratin 18 (NeoMarkers), Mucin-1 (NeoMarkers), b-Casein (Santa Cruz) and PECAM-1 (Santa Cruz). Tissue preparation and hematoxylin and eosin staining were carried out by the Histology Core Facility at Texas A&M University College of Veterinary Medicine and Biomedical Sciences. Immunostaining for SIM2s was performed on DCIS and IDC tissue sections provided by the University of KansasCancer Center Biospecimen Share Resources at the University of KansasMedical Center. CD31 quantification was performed using the ImageJ Software (NIH) and has been previously described. 61, 62 RNA isolation and reverse transcription RNA was isolated from tissues using Trizol Reagent (Invitrogen), followed by purification using a Qiagen RNEasy Mini Kit (Qiagen, Valencia, CA, USA) as previously described. 17 A measure of 2 mg total RNA was reverse transcribed into cDNA using oligo(dT) and Superscript II Reverse transcriptase (Invitrogen). Reverse Transcription reactions were performed on tissues as previously described. 63 Quantitative real-time PCR Q-PCR was performed as previously described. 17 Q-PCR was performed using SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA). Primers (IDT, Coralville, IA, USA) for analysis of SIM2s and CSN2 mRNA levels have been previously described, 18 as well as CDH1, SLUG and Ker18. 16 Primers used for further mRNA analysis include p21(forward primer: 5 0 -CCT-AAT-CCG-CCC-ACA-GGA-A-3 0 ; reverse primer: 5 0 -AAG-ATG-TAG-AGC-GGG-CCT-TTG-3 0 ), SMA (forward primer: 5 0 -CAA-GTG-ATC-ACC-ATC-GGA-AAT-G-3 0 ; reverse primer: 5 0 -AGC-AGA-CTC-CAT-CCC-GAT-GA-3 0 ), SMO (forward primer: 5 0 -CAC-CCT-GGC-CAC-ATT-CGT-3 0 ; reverse primer: 5 0 -CGC-ATT-GAC-GTA-GAA-GAG-AAT-AAC-A-3 0 ), p63 (forward primer: 5 0 -CCT-TCT-GTG-AGC-CAG-CTT-ATC-A-3 0 ; reverse primer: 5 0 -CAT-CAG-GAA-TGG-TTG-TAG-GAG-TGA-3 0 ), GATA3 (forward primer: 5 0 -CTG-GCT-CGC-AGA-ATT-GCA-3 0 ; reverse primer: 5 0 -AAC-TGG-GTA-TGG-CAG-AAT-AAA-ACG-3 0 ) and b-2-Globulin. 36 GAPDH and TBP were used as the normalizing genes, and data were analyzed using the DDC T method. 64 
